TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02558972
Drug: Northera (Droxidopa)
Normalized name: Northera
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP\>140mmHg or diastolic BP\>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
Study: NCT00457717
Drug: 0.25 % atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00457717
Drug: 0.5 % atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02153632
Drug: amantadine HCl ER
Normalized name: amantadine Extended Release Oral Capsule
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects are given either 240 mg amantadine HCl ER tablet or 320 mg amantadine HCl ER tablet
Study: NCT03353675
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 360 mg IV administration every 3 weeks
Study: NCT01917383
Drug: Trabodenoson
Normalized name: Trabodenoson
DrugBank: Trabodenoson (DB13122)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic eye drop
Study: NCT01917383
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ophthalmic eye drop
Study: NCT01917383
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ophthalmic eye drop
Study: NCT03760991
Drug: INSULIN GLARGINE (U300)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: Solution for injection in a prefilled pen~Route of administration: Subcutaneous
Study: NCT02485691
Drug: cabazitaxel XRP6258
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: intravenous
Study: NCT02485691
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT02485691
Drug: abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02485691
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT02961608
Drug: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
Study: NCT00604565
Drug: soluble ferric pyrophosphate (SFP)
DrugBank: Ferric pyrophosphate (DB09147)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).~Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)
Study: NCT03315741
Drug: Pirfenidone 267 MG [Esbriet]
Normalized name: pirfenidone 267 MG [Esbriet]
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolerability of drug
Study: NCT04631757
Drug: Camrelizumab + SOX + Radiotherapy
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200mg,d1,Q3w; oxaliplatin 130mg/m2, d1, Q3w; S-1 40-60mg bid, d1-d14,Q3w; intensity modulated radiotherapy 45Gy/25d
Study: NCT00039546
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00039546
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00039546
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00109239
Drug: rhuMAb VEGF (Bevacizumab)
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01485185
Drug: Gabapentin lower dose
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat, oral dose
Study: NCT01485185
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat, oral dose
Study: NCT01485185
Drug: Gabapentin higher dose
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repeat, oral dose
Study: NCT04203290
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: %0.25 bupivacaine solution
Study: NCT04203290
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: End tidal sevoflurane concentration
Study: NCT04312815
Drug: SM03
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: SM03: 600 mg intravenous (IV)
Study: NCT04312815
Drug: MTX
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate: 7.5-20 mg/wk oral
Study: NCT00911326
Drug: Lymphoseek
Normalized name: Lymphoseek
DrugBank: Tilmanocept (DB15373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
Study: NCT00544193
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03187626
Drug: botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Study: NCT00060684
Drug: Pixantrone (BBR 2778)
DrugBank: Pixantrone (DB06193)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00060684
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00060684
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00060684
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02395913
Drug: Surfolase capsule (100mg)
Normalized name: Surfolase
DrugBank: Ambroxol acefyllinate (DB13141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfolase capsule one capsule twice one days fasting administration
Study: NCT02395913
Drug: Surfolase CR (200mg, T1)
Normalized name: Surfolase
DrugBank: Ambroxol acefyllinate (DB13141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet once one days fasting administration.
Study: NCT02395913
Drug: Surfolase CR (200mg, T3)
Normalized name: T3
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one tablet once one days fasting administration.
Study: NCT02395913
Drug: Surfolase CR (200mg, T4)
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: one tablet once one days fasting administration.
Study: NCT03187626
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made thermoformed plastic splint to be worn for 48 hours after intra-articular injection then nightly
Study: NCT01499199
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50mg Once Daily
Study: NCT00955695
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00955695
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00779636
Drug: Desloratadine
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desloratadine 10 mg daily x 28 days
Study: NCT00969137
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous saline
Study: NCT00969137
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nicotine
Study: NCT04404686
Drug: Nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per os administration according to current protocol of 20mg each 20 minutes for 1 hour followed by 20 mg q8 for 48 hours.
Study: NCT01824524
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
Study: NCT02372253
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00716859
Drug: Timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol 0.5% dosed twice-daily
Study: NCT00716859
Drug: latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost 0.005% ophthalmic solution dosed once-daily
Study: NCT02473016
Drug: Carbon Dioxide Drug Delivery System (CDDS)
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doses will be administered to the nostril on the side of the trigeminal episode \[ipsilateral nostril\].
Study: NCT02260934
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96
Study: NCT02260934
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 0 and Week 2:~Solumedrol (100 mg) IV
Study: NCT02260934
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
Study: NCT02260934
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Week 0 and Week 2: Solumedrol (100 mg) IV
Study: NCT04292535
Drug: 20 IU NovoLog Insulin aspart into the intranasal mucosa
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT04292535
Drug: 40 IU NovoLog Insulin aspart into the intranasal mucosa
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT04292535
Drug: 60 IU NovoLog Insulin aspart into the intranasal mucosa
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT04292535
Drug: 80 IU NovoLog Insulin aspart into the intranasal mucosa
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT04292535
Drug: 100 IU NovoLog Insulin aspart into the intranasal mucosa
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT04292535
Drug: 120 IU NovoLog Insulin aspart into the intranasal mucosa
Normalized name: insulin aspart, human Cartridge [NovoLog]
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer
Study: NCT00644696
Drug: Irinotecan and Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
Study: NCT00633425
Drug: GLIMEPIRIDE
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02008461
Drug: botulinum toxin injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT02701257
Drug: Xeris Xerisol glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
Study: NCT02701257
Drug: Lilly glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: An aqueous formulation of human glucagon with limited stability that must be changed daily
Study: NCT00003612
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003612
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01109524
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
Study: NCT01109524
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
Study: NCT01109524
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
Study: NCT00847834
Drug: Irbesartan 150mg
Normalized name: IRBESARTAN 150MG TAB
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once a day
Study: NCT03101371
Drug: Catheter insertion with Povidone Iodine
Normalized name: Povidone-Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The catheter will be treated with Povidone Iodine prior to insertion.
Study: NCT00975039
Drug: WST11
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
Study: NCT00640549
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
Study: NCT02150967
Drug: BGJ398 (infigratinib)
Normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsule for oral use
Study: NCT00354484
Drug: Ferric Carboxymaltose (FCM)
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
Study: NCT03359967
Drug: Entresto tablet
Normalized name: Entresto
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Changes in intrathoracic impedance and other related parameters between before- and after Sacubitril/Valsartan treatment collected via previously implanted device algoritm. (OptiVol Fluid Index)
Study: NCT00354484
Drug: Ferrous Sulfate tablets
Normalized name: Ferrous Sulfate Tablets
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
Study: NCT02397772
Drug: albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of albendazole (400 mg)
Study: NCT00378534
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic
Study: NCT00378534
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic
Study: NCT02545738
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: active treatment
Study: NCT00152503
Drug: Seletracetam (UCB44212)
Normalized name: Levetiracetam
DrugBank: Seletracetam (DB05885)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Pharmaceutical form: oral capsules~* Concentration: 2, 10 and 50 mg~* Route of administration: oral administration
Study: NCT03399669
Drug: gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated 250 mg/day of gefitinib orally (1 cycle for 28 days). Cycles were repeated until disease progression, unacceptable toxicity, or until the patient or the investigator requested therapy discontinuation.
Study: NCT04044651
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenvatinib 12 mg (or 8 mg) by mouth (Po) once daily
Study: NCT04044651
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nivolumab 480 mg IV infusions for 30 minutes q4w
Study: NCT03322124
Drug: Octenidinedihydrochlorid
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
Study: NCT03664960
Drug: AK002
Normalized name: MONOCLONAL ANTIBODY AK002
DrugBank: Lirentelimab (DB16728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK002 is a humanized non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against Siglec-8.
Study: NCT01431612
Drug: Esmolol administration
DrugBank: Esmolol (DB00187)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
Study: NCT01431612
Drug: Phenylephrine infusion
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
Study: NCT01300234
Drug: Tenofovir disoproxil fumarate (TDF) tablets
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: white, almond-shaped, film-coated tablets containing 300mg of TDF
Study: NCT01300234
Drug: Adefovir dipivoxil (ADV) tablets
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: white to off-white, round, biconvex tablets containing 10mg of ADV
Study: NCT03590652
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4mg PO days 1,8,15 on 28-day cycle
Study: NCT03590652
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4mg days PO 1-21/28 days
Study: NCT03590652
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40mg\*\* PO weekly~\*\* starting dose for age \>75 may be 20mg
Study: NCT03590652
Drug: Daratumumab-Hyaluronidase-Fihj@1,800 Mg-30,000 Unit/15 mL@SUBCUT@VIAL (ML)
Normalized name: daratumumab-hyaluronidase-fihj@1,800 mg-30,000 unit/15 mL@SUBCUT@VIAL (ML)
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800mg SQ weekly x 8 weeks, biweekly x 8 doses, then monthly
Study: NCT00310765
Drug: Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks
Normalized name: pregabalin 150 MG
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days and treat for 7 weeks. Followed by open label pregabalin for 4 weeks at 150 mg BID